Mark Barrett

Mark Barrett is an accomplished biotechnology executive currently serving as Chief Business Officer at Madrigal Pharmaceuticals since 2024. As the Founder, CEO, and Board member of Lassen Therapeutics from 2018 to 2023, Mark led the company in developing novel antibody therapeutics, achieving key milestones in clinical development. Previously, Mark was an Entrepreneur-in-Residence at Frazier Healthcare Partners and held prominent positions at Genzyme, where responsibilities included global strategy and business development across various therapeutic areas. Earlier in the career, Mark contributed to Johnson & Johnson's innovation efforts and held roles in business development and research at Eli Lilly, ACADIA Pharmaceuticals, Digital Gene Technologies, Harvard Medical School, and Duke University Medical Center. Mark holds a BS in Biology from Duke University and an MBA in Finance from the University of California, Berkeley, Haas School of Business.